# Viemed Healthcare, Inc.: financial statements, quarterly

VMD · Nasdaq · CIK 1729149 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vmd.md) · [Financials](/companies/vmd/financials.md) · [Filings](/companies/vmd/filings.md) · [Insiders](/companies/vmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [49.4](/filings/0001729149-24-000210.md) | [50.7 d](/filings/0001729149-26-000009.md) | [50.6](/filings/0001729149-25-000096.md) | [55.0](/filings/0001729149-25-000119.md) | [58.0](/filings/0001729149-25-000149.md) | [60.7 d](/filings/0001729149-26-000009.md) | [59.1](/filings/0001729149-26-000029.md) | [63.1](/filings/0001729149-26-000042.md) | [71.9](/filings/0001729149-25-000149.md) | [76.2 d](/filings/0001729149-26-000009.md) | [75.4](/filings/0001729149-26-000029.md) | [78.1](/filings/0001729149-26-000042.md) |
| Cost of revenue | $m | [18.8](/filings/0001729149-24-000210.md) | [18.6 d](/filings/0001729149-26-000009.md) | [20.8](/filings/0001729149-25-000096.md) | [22.1](/filings/0001729149-25-000119.md) | [23.6](/filings/0001729149-25-000149.md) | [24.6 d](/filings/0001729149-26-000009.md) | [25.9](/filings/0001729149-26-000029.md) | [26.3](/filings/0001729149-26-000042.md) | [30.6](/filings/0001729149-25-000149.md) | [32.1 d](/filings/0001729149-26-000009.md) | [32.6](/filings/0001729149-26-000029.md) | [33.0](/filings/0001729149-26-000042.md) |
| Gross profit | $m | [30.6](/filings/0001729149-24-000210.md) | [32.1 d](/filings/0001729149-26-000009.md) | [29.8](/filings/0001729149-25-000096.md) | [32.9](/filings/0001729149-25-000119.md) | [34.4](/filings/0001729149-25-000149.md) | [36.1 d](/filings/0001729149-26-000009.md) | [33.3](/filings/0001729149-26-000029.md) | [36.7](/filings/0001729149-26-000042.md) | [41.3](/filings/0001729149-25-000149.md) | [44.1 d](/filings/0001729149-26-000009.md) | [42.8](/filings/0001729149-26-000029.md) | [45.0](/filings/0001729149-26-000042.md) |
| Research and development | $m | [0.6](/filings/0001729149-24-000210.md) | [0.7 d](/filings/0001729149-26-000009.md) | [0.8](/filings/0001729149-25-000096.md) | [0.8](/filings/0001729149-25-000119.md) | [0.8](/filings/0001729149-25-000149.md) | [0.8 d](/filings/0001729149-26-000009.md) | [0.8](/filings/0001729149-26-000029.md) | [0.8](/filings/0001729149-26-000042.md) | [0.8](/filings/0001729149-25-000149.md) | [0.6 d](/filings/0001729149-26-000009.md) | [0.6](/filings/0001729149-26-000029.md) | [0.5](/filings/0001729149-26-000042.md) |
| Selling, general and administrative | $m | [23.7](/filings/0001729149-24-000210.md) | [23.9 d](/filings/0001729149-26-000009.md) | [24.8](/filings/0001729149-25-000096.md) | [26.5](/filings/0001729149-25-000119.md) | [26.7](/filings/0001729149-25-000149.md) | [28.2 d](/filings/0001729149-26-000009.md) | [28.4](/filings/0001729149-26-000029.md) | [28.8](/filings/0001729149-26-000042.md) | [31.9](/filings/0001729149-25-000149.md) | [32.2 d](/filings/0001729149-26-000009.md) | [34.8](/filings/0001729149-26-000029.md) | [37.1](/filings/0001729149-26-000042.md) |
| Operating income | $m | [4.2](/filings/0001729149-24-000210.md) | [5.3 d](/filings/0001729149-26-000009.md) | [2.2](/filings/0001729149-25-000096.md) | [3.6](/filings/0001729149-25-000119.md) | [5.6](/filings/0001729149-25-000149.md) | [6.5 d](/filings/0001729149-26-000009.md) | [3.8](/filings/0001729149-26-000029.md) | [5.1](/filings/0001729149-26-000042.md) | [5.6](/filings/0001729149-25-000149.md) | [8.4 d](/filings/0001729149-26-000009.md) | [4.3](/filings/0001729149-26-000029.md) | [4.5](/filings/0001729149-26-000042.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.2](/filings/0001729149-26-000029.md) | [0.1](/filings/0001729149-26-000042.md) | not reported | not reported | [0.3](/filings/0001729149-26-000029.md) | [0.2](/filings/0001729149-26-000042.md) |
| Income tax | $m | [1.3](/filings/0001729149-24-000210.md) | [1.6 d](/filings/0001729149-26-000009.md) | [0.5](/filings/0001729149-25-000096.md) | [0.8](/filings/0001729149-25-000119.md) | [1.6](/filings/0001729149-25-000149.md) | [1.9 d](/filings/0001729149-26-000009.md) | [1.0](/filings/0001729149-26-000029.md) | [1.7](/filings/0001729149-26-000042.md) | [1.5](/filings/0001729149-25-000149.md) | [2.2 d](/filings/0001729149-26-000009.md) | [1.3](/filings/0001729149-26-000029.md) | [1.2](/filings/0001729149-26-000042.md) |
| Net income | $m | [2.9](/filings/0001729149-24-000210.md) | [3.5 d](/filings/0001729149-26-000009.md) | [1.6](/filings/0001729149-25-000096.md) | [1.5](/filings/0001729149-25-000119.md) | [3.9](/filings/0001729149-25-000149.md) | [4.3 d](/filings/0001729149-26-000009.md) | [2.6](/filings/0001729149-26-000029.md) | [3.2](/filings/0001729149-26-000042.md) | [3.5](/filings/0001729149-25-000149.md) | [5.6 d](/filings/0001729149-26-000009.md) | [2.6](/filings/0001729149-26-000029.md) | [2.8](/filings/0001729149-26-000042.md) |
| Diluted EPS | $ per share | [0.07](/filings/0001729149-24-000210.md) | not reported | [0.04](/filings/0001729149-25-000096.md) | [0.04](/filings/0001729149-25-000119.md) | [0.10](/filings/0001729149-25-000149.md) | not reported | [0.06](/filings/0001729149-26-000029.md) | [0.08](/filings/0001729149-26-000042.md) | [0.09](/filings/0001729149-25-000149.md) | not reported | [0.06](/filings/0001729149-26-000029.md) | [0.07](/filings/0001729149-26-000042.md) |
| Basic EPS | $ per share | [0.08](/filings/0001729149-24-000210.md) | not reported | [0.04](/filings/0001729149-25-000096.md) | [0.04](/filings/0001729149-25-000119.md) | [0.10](/filings/0001729149-25-000149.md) | not reported | [0.07](/filings/0001729149-26-000029.md) | [0.08](/filings/0001729149-26-000042.md) | [0.09](/filings/0001729149-25-000149.md) | not reported | [0.07](/filings/0001729149-26-000029.md) | [0.07](/filings/0001729149-26-000042.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.1](/filings/0001729149-23-000161.md) | [12.8](/filings/0001729149-25-000056.md) | [7.3](/filings/0001729149-24-000102.md) | [8.8](/filings/0001729149-24-000162.md) | [11.3](/filings/0001729149-24-000210.md) | [17.5](/filings/0001729149-26-000009.md) | [10.2](/filings/0001729149-25-000096.md) | [20.0](/filings/0001729149-25-000119.md) | [11.1](/filings/0001729149-25-000149.md) | [13.5](/filings/0001729149-26-000042.md) | [9.8](/filings/0001729149-26-000029.md) | [10.7](/filings/0001729149-26-000042.md) |
| Current assets | $m | [35.9](/filings/0001729149-23-000161.md) | [38.4](/filings/0001729149-25-000056.md) | [38.6](/filings/0001729149-24-000102.md) | [45.0](/filings/0001729149-24-000162.md) | [47.7](/filings/0001729149-24-000210.md) | [52.9](/filings/0001729149-26-000009.md) | [49.1](/filings/0001729149-25-000096.md) | [55.3](/filings/0001729149-25-000119.md) | [50.0](/filings/0001729149-25-000149.md) | [48.5](/filings/0001729149-26-000042.md) | [49.8](/filings/0001729149-26-000029.md) | [54.0](/filings/0001729149-26-000042.md) |
| Total assets | $m | [149](/filings/0001729149-23-000161.md) | [155](/filings/0001729149-25-000056.md) | [155](/filings/0001729149-24-000102.md) | [164](/filings/0001729149-24-000162.md) | [170](/filings/0001729149-24-000210.md) | [177](/filings/0001729149-26-000009.md) | [178](/filings/0001729149-25-000096.md) | [185](/filings/0001729149-25-000119.md) | [202](/filings/0001729149-25-000149.md) | [199](/filings/0001729149-26-000042.md) | [197](/filings/0001729149-26-000029.md) | [204](/filings/0001729149-26-000042.md) |
| Current liabilities | $m | [31.6](/filings/0001729149-23-000161.md) | [32.1](/filings/0001729149-25-000056.md) | [30.1](/filings/0001729149-24-000102.md) | [31.5](/filings/0001729149-24-000162.md) | [36.4](/filings/0001729149-24-000210.md) | [37.3](/filings/0001729149-26-000009.md) | [35.5](/filings/0001729149-25-000096.md) | [37.3](/filings/0001729149-25-000119.md) | [44.2](/filings/0001729149-25-000149.md) | [41.1](/filings/0001729149-26-000042.md) | [40.7](/filings/0001729149-26-000029.md) | [47.9](/filings/0001729149-26-000042.md) |
| Total liabilities | $m | [40.6](/filings/0001729149-23-000161.md) | [41.0](/filings/0001729149-25-000056.md) | [38.6](/filings/0001729149-24-000102.md) | [42.8](/filings/0001729149-24-000162.md) | [42.7](/filings/0001729149-24-000210.md) | [43.8](/filings/0001729149-26-000009.md) | [41.3](/filings/0001729149-25-000096.md) | [43.0](/filings/0001729149-25-000119.md) | [66.9](/filings/0001729149-25-000149.md) | [55.6](/filings/0001729149-26-000042.md) | [51.6](/filings/0001729149-26-000029.md) | [58.3](/filings/0001729149-26-000042.md) |
| Long-term debt | $m | [8.1](/filings/0001729149-23-000161.md) | [6.0](/filings/0001729149-25-000056.md) | [5.9](/filings/0001729149-24-000102.md) | [8.7](/filings/0001729149-24-000162.md) | [3.7](/filings/0001729149-24-000210.md) | [3.6](/filings/0001729149-26-000009.md) | [3.5](/filings/0001729149-25-000096.md) | [3.5](/filings/0001729149-25-000119.md) | [19.6](/filings/0001729149-25-000149.md) | [11.3](/filings/0001729149-26-000042.md) | [8.3](/filings/0001729149-26-000029.md) | [6.4](/filings/0001729149-26-000042.md) |
| Current portion of debt | $m | [1.8](/filings/0001729149-23-000161.md) | [1.1](/filings/0001729149-25-000056.md) | [0.6](/filings/0001729149-24-000102.md) | [0.8](/filings/0001729149-24-000162.md) | [0.8](/filings/0001729149-24-000210.md) | [0.4](/filings/0001729149-26-000009.md) | [0.4](/filings/0001729149-25-000096.md) | [0.8](/filings/0001729149-25-000119.md) | [1.6](/filings/0001729149-25-000149.md) | [1.1](/filings/0001729149-26-000042.md) | [0.9](/filings/0001729149-26-000029.md) | [0.7](/filings/0001729149-26-000042.md) |
| Shareholders' equity | $m | [109](/filings/0001729149-23-000161.md) | [114](/filings/0001729149-25-000056.md) | [116](/filings/0001729149-24-000102.md) | [119](/filings/0001729149-24-000162.md) | [125](/filings/0001729149-24-000210.md) | [131](/filings/0001729149-26-000009.md) | [135](/filings/0001729149-25-000096.md) | [140](/filings/0001729149-25-000119.md) | [134](/filings/0001729149-25-000149.md) | [142](/filings/0001729149-26-000042.md) | [144](/filings/0001729149-26-000029.md) | [144](/filings/0001729149-26-000042.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [13.8 d](/filings/0001729149-24-000210.md) | [13.3 d](/filings/0001729149-26-000009.md) | [1.2](/filings/0001729149-25-000096.md) | [10.2 d](/filings/0001729149-25-000119.md) | [12.7 d](/filings/0001729149-25-000149.md) | [15.0 d](/filings/0001729149-26-000009.md) | [2.9](/filings/0001729149-26-000029.md) | [12.3 d](/filings/0001729149-26-000042.md) | [18.4 d](/filings/0001729149-25-000149.md) | [18.4 d](/filings/0001729149-26-000009.md) | [8.1](/filings/0001729149-26-000029.md) | [15.9 d](/filings/0001729149-26-000042.md) |
| Capital expenditure | $m | [7.4 d](/filings/0001729149-24-000210.md) | [7.9 d](/filings/0001729149-26-000009.md) | [6.0](/filings/0001729149-25-000096.md) | [8.9 d](/filings/0001729149-25-000119.md) | [11.0 d](/filings/0001729149-25-000149.md) | [11.8 d](/filings/0001729149-26-000009.md) | [15.5](/filings/0001729149-26-000029.md) | [8.1 d](/filings/0001729149-26-000042.md) | [7.6 d](/filings/0001729149-25-000149.md) | [8.7 d](/filings/0001729149-26-000009.md) | [6.7](/filings/0001729149-26-000029.md) | [8.5 d](/filings/0001729149-26-000042.md) |
| Share repurchases | $m | [0.0 d](/filings/0001729149-23-000161.md) | [0.0 d](/filings/0001729149-26-000009.md) | not reported | not reported | [0.0 d](/filings/0001729149-25-000149.md) | [0.0 d](/filings/0001729149-26-000009.md) | [0.0](/filings/0001729149-26-000029.md) | [1.7 d](/filings/0001729149-26-000042.md) | [11.6 d](/filings/0001729149-25-000149.md) | [0.0 d](/filings/0001729149-26-000009.md) | [1.4](/filings/0001729149-26-000029.md) | [5.3 d](/filings/0001729149-26-000042.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.6](/filings/0001729149-23-000161.md) | [40.0](/filings/0001729149-24-000102.md) | [40.7](/filings/0001729149-24-000162.md) | [40.4](/filings/0001729149-24-000210.md) | [40.6](/filings/0001729149-25-000096.md) | [40.6](/filings/0001729149-25-000119.md) | [40.8](/filings/0001729149-25-000149.md) | [41.6](/filings/0001729149-26-000029.md) | [41.1](/filings/0001729149-26-000042.md) | [40.5](/filings/0001729149-25-000149.md) | [40.5](/filings/0001729149-26-000029.md) | [41.1](/filings/0001729149-26-000042.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 38,088,228 at 2026-07-27, from the cover of the [10-Q filed 2026-08-03](/filings/0001729149-26-000042.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.